The technology, known as Verifi, is available with the ChargePoint’s range of valves that ensure safe and contamination-free handling of API and other formulation ingredients.
ChargePoint Technology, a supplier of powder containment and aseptic transfer valve, has launched a smart monitoring hub to support efficiency and safety within chemical and pharmaceutical manufacturing processes. The company will be exhibiting its new Verifi solution at Achema 2018.
ChargePoint contained transfer devices are used to ensure integrity of product handling during high potency and sterile manufacturing. With Verifi, manufacturers have an automatic and reliable method of understanding the health status of the device, allowing them to better control risk and ensure consistent integrity throughout the lifecycle of the system and its critical components.
Verifi is connected directly onto the ChargePoint active valve unit; it continuously records data and delivers alerts to its users. Its LED display provides operators with visual feedback. Service advice allows maintenance teams to take preventative action, resulting in less downtime and improved efficiency.
Data can also be synchronized via WiFi to the secure Verifi portal, where data are stored in the cloud for production and process managers to analyse remotely and export for further reporting.
ChargePoint Technology’s other solutions include its AseptiSafe range, which provides increased sterility assurance for ingredient and small component transfers in aseptic processing and sterile API production. The PharmaSafe powder containment valves offer high level of containment performance to ensure the safe handling of potent APIs, intermediates, and pharmaceutical formulations.
Source: ChargePoint, Hall 3.0, Booth D14
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.